Medical devices, healthcare technology and the business of care
PMA approval · P150025

PD-L1 IHC 28-8 pharmDx

Agilent Technologies, Inc. · Decision date Oct 9, 2015

FDA DECISIONP150025

What did the FDA approve?

FDA records P150025 as an original PMA application. The recorded decision is approval, dated Oct 9, 2015.

FDA approval order statement

APPROVAL FOR THE PD-L1 IHC 28-8 PHARMDX. THIS DEVICE IS INDICATED FOR THE FOLLOWING:1) PD-L1 IHC 28-8 PHARMDX IS A QUALITATIVE IMMUNOHISTO-CHEMICAL ASSAY USING MONOCLONAL RABBIT ANTI-PD-L1, CLONE 28-8 INTENDED FOR USE IN THE DETECTION OF PD-L1 PROTEIN IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE USING ENVISION FLEX VISUALIZATION SYSTEM ON AUTOSTAINER LINK 48; 2) PD-L1 PROTEIN EXPRESSION IS DEFINED AS THE PERCENTAGE OF TUMOR CELLS EXHIBITING POSITIVE MEMBRANE STAINING AT ANY INTENSITY; AND3) PD-L1 EXPRESSION AS DETECTED BY PD-L1 IHC 28-8 PHARMDX IN NON-SQUAMOUS NSCLC MAY BE ASSOCIATED WITH ENHANCED SURVIVAL FROM OPDIVO (NIVOLUMAB).
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Oct 9, 2015

FDA source record

Regulatory record facts

Identifier
P150025
Regulatory pathway
Premarket approval application
Product code
Not reported
Decision code
APPR
Decision date
Oct 9, 2015
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

Product code
Not reported

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P150025 received

    Application receipt date recorded by FDA.

  2. P150025 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P150025. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150025

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5301 Stevens Creek Blvd., Santa Clara, CA, 95051

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records